Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analyst consensus: Teva has an average rating of "Moderate Buy" from 11 analysts with a one-year average price target of $37.67, and several firms have raised targets as high as $45.
• Quarterly results: Teva beat estimates with $0.96 EPS versus $0.65 expected and $4.71B revenue versus $4.36B, and set FY2026 guidance of $2.570–2.770 EPS (consensus ~2.5).
• Insider activity: Insiders sold about 948,499 shares (~$30.9M) in the last three months, leaving insider ownership near 0.49%.

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) have earned an average rating of "Moderate Buy" from the eleven ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, nine have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $37.6667.

TEVA has been the topic of a number of recent analyst reports. Bank of America increased their target price on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a "buy" rating in a research report on Tuesday, December 9th. Jefferies Financial Group raised their price objective on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a "buy" rating in a report on Tuesday, January 6th. The Goldman Sachs Group lifted their target price on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a "buy" rating in a research report on Monday, February 9th. Barclays boosted their target price on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an "overweight" rating in a report on Friday, January 30th. Finally, Piper Sandler reissued an "overweight" rating and issued a $41.00 target price (up from $40.00) on shares of Teva Pharmaceutical Industries in a research report on Wednesday, March 4th.

Insiders Place Their Bets

In related news, EVP Christine Fox sold 7,924 shares of the company's stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $250,953.08. Following the completion of the sale, the executive vice president owned 84,905 shares in the company, valued at $2,688,941.35. This represents a 8.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Eric A. Hughes sold 9,533 shares of the stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $301,910.11. Following the sale, the insider owned 107,711 shares of the company's stock, valued at approximately $3,411,207.37. This represents a 8.13% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 948,499 shares of company stock valued at $30,897,071. 0.49% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Corient Private Wealth LLC grew its holdings in shares of Teva Pharmaceutical Industries by 28.4% during the fourth quarter. Corient Private Wealth LLC now owns 49,063 shares of the company's stock worth $1,531,000 after buying an additional 10,843 shares during the last quarter. Dorsey Wright & Associates acquired a new position in Teva Pharmaceutical Industries in the 4th quarter valued at about $1,640,000. Compound Planning Inc. purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at approximately $323,000. Invesco Ltd. raised its stake in Teva Pharmaceutical Industries by 4.8% during the 4th quarter. Invesco Ltd. now owns 2,710,105 shares of the company's stock valued at $84,582,000 after acquiring an additional 124,304 shares during the last quarter. Finally, Alpine Woods Capital Investors LLC acquired a new stake in Teva Pharmaceutical Industries during the 4th quarter worth approximately $463,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $28.54 on Friday. The company has a market capitalization of $32.81 billion, a price-to-earnings ratio of 23.78, a price-to-earnings-growth ratio of 9.81 and a beta of 0.72. Teva Pharmaceutical Industries has a 52-week low of $12.47 and a 52-week high of $37.35. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. The stock has a 50 day moving average price of $32.91 and a 200 day moving average price of $26.62.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, topping analysts' consensus estimates of $0.65 by $0.31. The company had revenue of $4.71 billion for the quarter, compared to analysts' expectations of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The firm's revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter last year, the company earned $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Research analysts predict that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.